Guidance

Pharmaceutical Price Regulation Scheme

The 2009 PPRS is a five-year voluntary scheme effective from 1 January 2009, agreed between Government and the pharmaceutical industry.

Documents

Pharmaceutical Price Regulation Scheme 2009 (PPRS)

This file may not be suitable for users of assistive technology. Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dh.gsi.gov.uk . Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

PPRS will mean more patients will benefit from innovative drug treatments at a fair price to the NHS. The PPRS includes for the first time support for innovation and uptake of clinically and cost effective medicines. It also includes two provisions – more flexible pricing arrangements and more systematic use of patient access schemes – aimed at increasing patient access to medicines and ensuring the prices of medicines better reflect their value.

The objectives for the 2009 scheme, as stated in the agreement, are that it should:

Deliver value for money

Deliver value for money for the NHS by securing the provision of safe and effective medicines at reasonable prices, and encouraging the efficient development and competitive supply of medicines.

Encourage innovation

Promote a strong and profitable pharmaceutical industry that is both capable and willing to invest in sustained research and development to encourage the future availability of new and improved medicines for the benefit of patients and industry in this and other countries.

Promote access and uptake for new medicines

The Department of Health and industry are committed to increasing uptake and patient access for new clinically and cost-effective medicines in the NHS in a sustainable manner.

Provide stability, sustainability and predictability

To help the NHS and industry develop sustainable financial and investment strategies, the UK must remain a stable and predictable market that does not place unforeseen burdens on either party over the coming years.

Published 11 December 2008